Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with clostridium difficile-associated diarrhea

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4501-4505

  Clutter, Dana S ^a   Dubrovskaya, Yanina ^a   Merl, Man Yee ^a   Teperman, Lewis ^a   Press, Robert ^a   Safdar, Amar ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG TOLERABILITY; FECES CULTURE; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SALVAGE THERAPY; TABLET; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AMINOGLYCOSIDES; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; ORGAN TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84882425248     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01120-13     Document Type: Article

References (15)

1. Bobak D, Arfons LM, Creger RJ, Lazarus HM. 2008. Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm? Bone Marrow Transplant. 42:705-713.
2. Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, Marr KA. 2012. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 54:1053-1063.
3. Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, Wilt TJ. 2011. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann. Intern. Med. 155:839-847.
4. Collini PJ, Bauer M, Kuijper E, Dockrell DH. 2012. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J. Infect. 64:131-147.
5. Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, Michel JA, Dickson RC, Hughes C, Nguyen J, Chua H, Hellinger W. 2007. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl. Int. 20:856-866.
6. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. 2009. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53: 261-263.
7. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficileinfected patients than does vancomycin. Microbiology 156:3354-3359.
8. Optimer Pharmaceuticals. 2011. Dificid package insert. Optimer Pharmaceuticals, San Diego, CA.
9. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin. Infect. Dis. 55(Suppl 2):S121-S126. doi:10.1093/cid/cis440.
10. Matar MJ, Safdar A, Rolston KV. 2006. Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. Clin. Infect. Dis. 42:1506-1507.
11. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
12. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12:281-289.
13. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE, Study 003/004 Teams. 2012. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55(Suppl 2):S93-S103. doi:10.1093/cid/cis499.
14. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. 2012. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55(Suppl 2):S154-S161. doi:10 .1093/cid/cis462.
15. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. 2011. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53:440-447.